Keros Therapeutics reports Q4 2023 net loss of $40.2M, cash $331.1M; extends runway into 2027

Keros Therapeutics, Inc.

2023-FY EPS reported -$5.20 revenue$151,000

Net loss of $40.2M in Q4 2023 ($153.0M for FY) vs $29.7M and $104.7M in prior year periods.
Revenue of $0.2M in 2023 from license agreement with Hansoh; no revenue in 2022.
R&D expenses rose to $37.5M in Q4 (FY $135.3M) driven by Phase 2 trials of KER-050 and KER-012.
Cash and equivalents $331.1M at Dec 31, 2023; January 2024 public offering of 4.025M shares at $40/sh adds net proceeds, funding into 2027.
Anticipated milestones: Phase 3 trial design for KER-050 in MDS in H1 2024; data readouts throughout 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.2 million for the year ended December 31, 2023, net income a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $0.2 million for the year ended December 31, 2023
Net income: a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023
Result: reported results

Exact text from the filing

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-24-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.